Home › Compound Library › Selegiline

Selegiline

Nootropicprescriptionoral · inferred

Irreversible selective MAO-B inhibitor used as adjunctive therapy in Parkinson's disease and with growing interest in longevity and cognitive literature. At 5-10 mg/day oral, MAO-B selectivity largely spares tyramine pressor response; higher doses lose selectivity. Low oral bioavailability (~10%) due to extensive first-pass metabolism to L-amphetamine and L-methamphetamine metabolites. Transdermal formulation bypasses first-pass for MDD indication.

Projected serum levels — 5 mg, once daily

Selegiline
Selegiline modeled serum levels, 5 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Selegiline modeled serum levels with a loading dose of 6.2 mg, then 5 mg once daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 5 mg once daily (oral).

Loading schedule: 6.2 mg on day 1, then 5 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.59 mg, trough ≈ 0.12 mg body load. Population-based estimate over 15 days for a 5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Nootropic
Route modeled
Oral
Model confidence
inferred
Half-life
10 h
Common dose
5 mg
Suggested maximum
10 mg/day
Reference dose range
2.5–10 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.003 mg/L at 0.75 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Selegiline Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Selegiline Serotonin risk

    25I-NBOMe and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Selegiline Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Selegiline Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Selegiline Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Selegiline Serotonin risk

    4-AcO-DMT (Psilacetin) and Selegiline both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 162 modeled interaction pairings for selegiline across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Effect of deprenyl on the progression of disability in early Parkinson's disease (DATATOP) Parkinson Study Group · New England Journal of Medicine, 1989 DOI

    DATATOP RCT of 800 early PD patients showed selegiline 10 mg/day delayed the need for levodopa by ~9 months, establishing its role in early Parkinson's disease management.

  2. The pharmacology of selegiline Magyar K · International Review of Neurobiology, 2011 DOI

    Comprehensive pharmacology review covering selegiline's MAO-B selectivity, amphetamine metabolite contribution, neuroprotective mechanisms explored in preclinical models, and clinical applications.

  3. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain Knoll J · Pharmacology & Toxicology, 1993 DOI

    Foundational paper by Joseph Knoll describing selegiline's distinct catecholaminergic activity-enhancing effect independent of MAO-B inhibition, underpinning subsequent longevity and cognition hypotheses.

3 published studies referenced in the app, each with a plain-language summary.